UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Infection Risk and Safety of Corticosteroid Use

Rheumatic diseases clinics of North America, 2016-02, Vol.42 (1), p.157-176

2016

Volltextzugriff (PDF)

Nontuberculous Mycobacteria Infections in Immunosuppressed Hosts

Clinics in chest medicine, 2015-03, Vol.36 (1), p.91-99

2015

Volltextzugriff (PDF)

Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline

The European respiratory journal, 2020-07, Vol.56 (1), p.2000535

2020

Volltextzugriff (PDF)

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

Clinical infectious diseases, 2020-08, Vol.71 (4), p.e1-e36

2020

Volltextzugriff (PDF)

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

Clinical infectious diseases, 2020-08, Vol.71 (4), p.905-913

2020

Volltextzugriff (PDF)

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

Annals of the rheumatic diseases, 2022-03, Vol.81 (3), p.335-343

2022

Volltextzugriff (PDF)

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Annals of the rheumatic diseases, 2017-07, Vol.76 (7), p.1253-1262

2017

Volltextzugriff (PDF)

Nontuberculous Mycobacterial Disease Prevalence and Risk Factors: A Changing Epidemiology

Clinical infectious diseases, 2009-12, Vol.49 (12), p.e124-e129

2009

Volltextzugriff (PDF)

The emerging safety profile of JAK inhibitors in rheumatic disease

Nature reviews. Rheumatology, 2017-04, Vol.13 (4), p.234-243

Winthrop, Kevin L

2017

Volltextzugriff (PDF)

Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008-2015

Annals of the American Thoracic Society, 2020-02, Vol.17 (2), p.178-185

2020

Volltextzugriff (PDF)

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy

Arthritis & rheumatology (Hoboken, N.J.), 2017-10, Vol.69 (10), p.1960-1968

2017

Volltextzugriff (PDF)

Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis

The European respiratory journal, 2019-07, Vol.54 (1), p.1801896

2019

Volltextzugriff (PDF)

Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department

Journal of cataract and refractive surgery, 2013-01, Vol.39 (1), p.8-14

2013

Volltextzugriff (PDF)

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Annals of the rheumatic diseases, 2023-01, Vol.82 (1), p.107-118

2023

Volltextzugriff (PDF)

Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease

American journal of respiratory and critical care medicine, 2017-03, Vol.195 (6), p.814-823

2017

Volltextzugriff (PDF)

Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force

Annals of the Rheumatic Diseases, 2016-06, Vol.75 (6), p.952-957

2016

Volltextzugriff (PDF)

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

Annals of the rheumatic diseases, 2016-04, Vol.75 (4), p.687-695

2016

Volltextzugriff (PDF)

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

American journal of clinical dermatology, 2021-09, Vol.22 (5), p.693-707

2021

Volltextzugriff (PDF)

Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Annals of the rheumatic diseases, 2023-01, Vol.82 (1), p.95-106

2023

Volltextzugriff (PDF)

Surveillance of Extrapulmonary Nontuberculous Mycobacteria Infections, Oregon, USA, 2007-2012

Emerging infectious diseases, 2017-10, Vol.23 (10), p.1627-1630

2017

Volltextzugriff (PDF)

Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis

Annals of the rheumatic diseases, 2017-03, Vol.76 (3), p.543-546

2017

Volltextzugriff (PDF)

Treatment of Mycobacterium abscessus Infection

Emerging infectious diseases, 2016-03, Vol.22 (3), p.511-514

2016

Volltextzugriff (PDF)

Epidemiology of nontuberculous mycobacterial infections in the U.S. Veterans Health Administration

PloS one, 2018-06, Vol.13 (6), p.e0197976-e0197976

2018

Volltextzugriff (PDF)

Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Annals of the rheumatic diseases, 2023-01, Vol.82 (1), p.81-94

2023

Volltextzugriff (PDF)

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

Emerging infectious diseases, 2009-10, Vol.15 (10), p.1556-1561

2009

Volltextzugriff (PDF)

1 – 25 von 398

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(383)
Mit Volltextzugriff
(283)

Publikationsform

Sprache

Englisch
(398)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(287)
Life Sciences & Biomedicine
(284)
Humans
(223)
Rheumatology
(121)
Female
(109)
Male
(103)
Middle Aged
(82)
Rheumatoid Arthritis
(80)
Infectious Diseases
(73)
Patients
(67)
Aged
(66)
Adult
(65)
Infections
(64)
Arthritis, Rheumatoid - Drug Therapy
(58)
Respiratory System
(58)
Risk Factors
(52)
Clinical Trials
(46)
Nontuberculous Mycobacteria
(45)
Immunology
(41)
Antirheumatic Agents - Therapeutic Use
(40)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Infection Risk and Safety of Corticosteroid Use

Nontuberculous Mycobacteria Infections in Immunosuppressed Hosts

Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

Nontuberculous Mycobacterial Disease Prevalence and Risk Factors: A Changing Epidemiology

The emerging safety profile of JAK inhibitors in rheumatic disease

Incidence and Prevalence of Nontuberculous Mycobacterial Lung Disease in a Large U.S. Managed Care Health Plan, 2008-2015

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy

Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis

Decreased postoperative endophthalmitis rate after institution of intracameral antibiotics in a Northern California eye department

Safety of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Randomized Trial of Liposomal Amikacin for Inhalation in Nontuberculous Mycobacterial Lung Disease

Defining conditions where long-term glucocorticoid treatment has an acceptably low level of harm to facilitate implementation of existing recommendations: viewpoints from an EULAR task force

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Efficacy of synthetic and biological DMARDs: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Surveillance of Extrapulmonary Nontuberculous Mycobacteria Infections, Oregon, USA, 2007-2012

Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis

Treatment of Mycobacterium abscessus Infection

Epidemiology of nontuberculous mycobacterial infections in the U.S. Veterans Health Administration

Efficacy, duration of use and safety of glucocorticoids: a systematic literature review informing the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis

Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy

Suchergebnisse filtern